Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | NEK2 | P51955 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14142621 | 0.80 | ALDH1A1 (0.43) | MAPTALDH1A1GAATSHRTP53 | |
| SCHEMBL770158 | 0.80 | MAPT (0.43) | MAPTALDH1A1GAATSHRTP53 | |
| SCHEMBL2904764 | 0.76 | MAPT (0.40) | MAPTALDH1A1GAATSHRTP53 | |
| SCHEMBL97296 | 0.76 | ALDH1A1 (0.45) | MAPTALDH1A1GAATSHRTP53 | |
| SCHEMBL1330188 | 0.76 | ALDH1A1 (0.40) | MAPTALDH1A1GAATSHRTP53 | |
| SCHEMBL148781 | 0.76 | ALDH1A1 (0.55) | MAPTALDH1A1GAATSHRTP53 | |
| Iodide SCHEMBL31276096 | 0.74 | ALDH1A1 (0.53) | MAPTALDH1A1GAATSHRTP53 | |
| SCHEMBL14565683 | 0.74 | MAPT (0.39) | MAPTALDH1A1GAATSHRTP53 | |
| SCHEMBL2923196 | 0.73 | ALDH1A1 (0.37) | MAPTALDH1A1KDM4ETDP1L3MBTL1 | |
| SCHEMBL9126953 | 0.73 | MAPT (0.39) | MAPTALDH1A1GAATSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7408060-B2 | Nonsteroidal progesterone receptor modulators | SCHERING AG (DE) | 2008-08-05 | — | — | US | claimed |
| EP-1902049-A2 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | claimed |
| EP-1899315-A1 | BENZOFURANONE DERIVATIVES AS NONSTEROIDAL PROGESTERONE RECEPTOR MODULATORS | Schering Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | claimed |
| US-20070142464-A1 | Nonsteroidal progesterone receptor modulators | SCHERING AG (DE) | 2007-06-21 | — | — | US | claimed |
| US-20070010514-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-11 | — | — | US | claimed |
| WO-2006136462-A1 | BENZOFURANONE DERIVATIVES AS NONSTEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | claimed |
| WO-2006136461-A2 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-12-28 | — | — | WO | claimed |
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
| WO-2009122148-A1 | FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009071895-A1 | FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071890-A1 | TRICYCLIC KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-06-11 | — | — | WO | disclosed |
| EP-1674460-B1 | CHROMENE COMPOUND | TOKUYAMA CORP (JP) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007141504-A1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2007-12-13 | — | — | WO | disclosed |
| US-20070215844-A1 | Chromene Compound | TOKUYAMA CORPORATION (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1674460-A1 | CHROMENE COMPOUND | Tokuyama Corporation (JP) | 2006-06-28 | — | — | EP | disclosed |
| EP-1054010-B1 | Chromene compound | TOKUYAMA CORP (JP) | 2002-07-24 | — | — | EP | disclosed |
| US-6340765-B1 | PHOTOCHROMIC DYES AND DEVELOPMENT | TOKUYAMA CORPORATION (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1054010-A1 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2000-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010514-A1 | Non-steroidal progesterone receptor modulators | PGR, PGRMC1, CYP19A1 | MAPT 4874/4885ALDH1A1 1444/4885GAA 4824/4885 |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | MAPT 790/4885ALDH1A1 3061/4885GAA 1593/4885 |
| US-20070215844-A1 | Chromene Compound | CRY2, TYR, CRY1 | MAPT 520/4885ALDH1A1 2110/4885GAA 4597/4885 |
| US-20070142464-A1 | Nonsteroidal progesterone receptor modulators | PGR, PGRMC1, PGRMC2 | MAPT 4841/4885ALDH1A1 1023/4885GAA 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.